Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.
https://european-biotechnology.com/wp-content/uploads/2025/01/Arctic_Therapeutics-e1737542077825.png7481592Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2025-01-22 11:37:442025-01-22 14:33:11Arctic Therapeutics ASA kicks off with €26.5m Series A round